With strength, Hengrui applied for four new drugs of category 1.1 in 2014
-
Last Update: 2015-01-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Shr7390 tablets of Hengrui medicine were undertaken by CDE on December 31, 2014 and entered the evaluation center However, the relevant information of shr7390 is not available at present As the leading innovative drug R & D in China, Hengrui pharmaceutical has not only obtained the production approval documents of apatinib mesylate in the past year, but also applied for 4 new drugs of 1.1 type (see the table below) The 4th new drug of 1.1 type, shr7390, has grasped the tail of 2014, and the acceptance number has been undertaken to enter the review center on the last day.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
